Actively Recruiting
Phase 2 Study Evaluating CRD-4730 for Safety and Effectiveness in Adults with Heart Failure and Reduced Heart Pump Function
Led by Cardurion Pharmaceuticals, Inc. · Updated on 2026-08-06
525
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating CRD-4730, a calciumcalmodulin-dependent protein kinase II CaMKII inhibitor, in adults with heart failure with reduced ejection fraction HFrEF. This Phase 2, global, multi-center trial aims to assess the safety, tolerability, and effectiveness of CRD-4730 alongside guideline-directed medical therapy. Participants have chronic heart failure with a reduced heart pump function and are classified as New York Heart Association NYHA class II to III. Participants are randomly assigned to one of four groups to receive either one of three doses of CRD-4730 or a matching placebo. The study drug or placebo is given orally twice daily for a treatment period of 24 weeks. This double-blind trial ensures that neither participants nor researchers know which treatment is administered during the study. During the trial, participants undergo assessments including heart function tests, blood biomarker measurements, and questionnaires at baseline, mid-treatment week 12, and after 24 weeks of treatment. The main outcome measured is the change from baseline in a composite score at 24 weeks. Safety and response are monitored throughout, with total participation lasting about six months.
CONDITIONS
Brief Title
A Trial of CRD-4730 in HFrEF
Research Team
C
Cardurion Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
